TP53 and acute myeloid leukemia: It is important to note that our follow-up period was only three years, and thus, the incidence of clonal evolution, particularly in patients with mutations in ASXL1, DNMT3A, RUNX1, and TP53, which are more likely to convert to AML/MDS, requires close attention during follow-up.